SynthesisMolecular systems biology2011
A pharmacogenomic method for individualized prediction of drug sensitivity.
Synthesis in Molecular systems biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Pan-cancer analysis identifies DBF4B as an immunologic and prognostic biomarker.Journal of Cancer · 2025Article
- Small molecule-mediated targeting of microRNAs for drug discovery: Experiments, computational techniques, and disease implications.European journal of medicinal chemistry · 2023Review
- The impact of violating the independence assumption in meta-analysis on biomarker discovery.Frontiers in genetics · 2022Article
- Comparing the Predictivity of Human Placental Gene, microRNA, and CpG Methylation Signatures in Relation to Perinatal Outcomes.Toxicological sciences : an official journal of the Society of Toxicology · 2021Article
- Topsentinol L Trisulfate, a Marine Natural Product That Targets Basal-like and Claudin-Low Breast Cancers.Marine drugs · 2021Article
- Embryo-derived teratoma in vitro biological system reveals antitumor and embryotoxic activity of valproate.The FEBS journal · 2020Article
- Sex-Biased Molecular Signature for Overall Survival of Liver Cancer Patients.Biomolecules & therapeutics · 2020Review
- Tumor-stroma interactions differentially alter drug sensitivity based on the origin of stromal cells.Molecular systems biology · 2018Article
- Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes.Genome medicine · 2017Article
- Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker.JCO precision oncology · 2017Article
- Entropy-based divergent and convergent modular pattern reveals additive and synergistic anticerebral ischemia mechanisms.Experimental biology and medicine (Maywood, N.J.) · 2016Article
- Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.The Journal of biological chemistry · 2016Article
- Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action.PLoS computational biology · 2015Article
- Article
- From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects.Archives of toxicology · 2014Article
- Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.Breast cancer research : BCR · 2014Article
- Article
- Personalized management of chronic obstructive pulmonary disease via transcriptomic profiling of the airway and lung.Annals of the American Thoracic Society · 2013Review
- Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.BMC medical genomics · 2013Article
- Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine.Current protocols in pharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Identifying the best drug for each cancer patient requires an efficient individualized strategy. We present MATCH (Merging genomic and pharmacologic Analyses for Therapy CHoice), an approach using public genomic resources and drug testing of fresh tumor samples to link drugs to patients. Valproic acid (VPA) is highlighted as a proof-of-principle. In order to predict specific tumor types with high probability of drug sensitivity, we create drug response signatures using publically available gene expression data and assess sensitivity in a data set of >40 cancer types. Next, we evaluate drug sensitivity in matched tumor and normal tissue and exclude cancer types that are no more sensitive than normal tissue. From these analyses, breast tumors are predicted to be sensitive to VPA. A meta-analysis across breast cancer data sets shows that aggressive subtypes are most likely to be sensitive to VPA, but all subtypes have sensitive tumors. MATCH predictions correlate significantly with growth inhibition in cancer cell lines and three-dimensional cultures of fresh tumor samples. MATCH accurately predicts reduction in tumor growth rate following VPA treatment in patient tumor xenografts. MATCH uses genomic analysis with in vitro testing of patient tumors to select optimal drug regimens before clinical trial initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.